Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.

Bo Kyung KimHyoung Jin KangKyung Taek HongHong Yul AnJung Yoon ChoiJee Soo LeeSung Sup ParkHee Young Shin

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2019)

In conclusion, preemptive therapy containing rituximab is expected to reduce the incidence of PTLD after HSCT and improve post-transplantation outcomes in children.

Keyphrases

epstein barr virus
diffuse large b cell lymphoma
young adults
risk factors
acute myeloid leukemia
cell therapy
adipose tissue
bone marrow
insulin resistance